OQROSign up free
Insider trade

Aim Immunotech (AIM): CEO bought ~$2.3K

Thomas K Equels, CEO at Aim Immunotech, bought ~$2.3K of Aim Immunotech shares.

~$2.3K
Approx. value · 11K sh @ $0.21
103K
Holds after · shares reported
Traded
Sep 16, 2026
Filed
Sep 17, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Jul 31, 2026Company filing · Form 8-K · Agreement endedEnded an important agreement
  2. Jul 31, 2026Company filing · Form 8-K · Material agreement, Shareholder Director NominationsSigned an important agreement, and set the date for shareholder nominations
  3. Aug 7, 2026Company filing · Form 8-K · ResultsReported its results
  4. Aug 31, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 1 more item)
  5. Sep 3, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  6. Sep 8, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
  7. Sep 14, 2026Insider · First insider buy since Jun 2025CEO purchased ~$1.3K of AIM shares in the open market
  8. Sep 15, 2026InsiderCEO purchased ~$4.9K of AIM shares in the open market
  9. Sep 16, 2026 · this disclosureInsiderCEO purchased ~$2.3K of AIM shares in the open market

What came next

  1. Sep 17, 2026InsiderCEO purchased ~$5K of AIM shares in the open market
  2. Oct 22, 2026InsiderCEO purchased ~$5.1K of AIM shares in the open market
  3. Oct 23, 2026InsiderCEO purchased ~$5.1K of AIM shares in the open market
  4. Nov 6, 2026Insider · 1 personInsiders: 2 purchases (~$5K)
  5. Nov 9, 2026InsiderCEO purchased ~$5.1K of AIM shares in the open market
  6. Nov 10, 2026InsiderCEO purchased ~$5.4K of AIM shares in the open market
  7. Nov 11, 2026InsiderCEO purchased ~$5.2K of AIM shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Aim Immunotech

For Aim Immunotech, OQRO holds 11 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AIM page.

Other recent filings by Thomas K Equels, CEO & President

The full history of Thomas K Equels, CEO & President is on the profile page.

How this filing works

Explore the data

Other disclosures at Aim Immunotech

Everything OQRO holds on this company is on its AIM page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data